Tesamorelin
Tesamorelin is an intensely potent, FDA-approved Growth Hormone Releasing Hormone (GHRH) analog utilized medically under the brand name Egrifta. Unlike traditional secretagogues that induce generalized systemic effects, Tesamorelin displays an extraordinary, highly specific affinity for annihilating deep visceral adipose tissue (VAT). Originally designed to combat severe lipodystrophy in HIV patients, it is the premier clinical choice for aggressively reversing visceral fat accumulation, reversing hepatic steatosis (fatty liver), and drastically improving systemic lipid profiles without causing severe insulin resistance.
Quick Stats
Scientific Data
Mechanism of Action
Tesamorelin is a synthetic analog of GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminal for enhanced stability. It is the only FDA-approved GHRH analog (Egrifta), approved for HIV-associated lipodystrophy (excess visceral and truncal fat).
Tesamorelin binds GHRH receptors in the pituitary, stimulating pulsatile Growth Hormone release. Unlike exogenous GH, it preserves the natural pulsatile GH rhythm and hypothalamic feedback loop. It specifically reduces visceral adipose tissue (VAT) and has shown improvements in cognitive function, cardiovascular markers, and body composition in both HIV+ and general populations.
Source: FDA Label (Egrifta), PMID: 20947872
Background & History
Tesamorelin (Egrifta) is an FDA-approved synthetic GHRH analog developed by Theratechnologies for lipodystrophy in HIV patients. It is the only GHRH analog approved for human use in the United States. A modified version of native GHRH with the addition of a trans-3-hexenoic acid group for protease stability, it has a longer half-life (~30 min) than native GHRH (~7 min). Clinical trials showed 15–18% reduction in visceral adipose tissue — the most consistent pharmacological reduction of visceral fat demonstrated in clinical trials.
Research Use Cases
- ✓HIV-associated lipodystrophy (FDA approved, Egrifta)
- ✓Visceral adiposity reduction independent of HIV status (off-label research)
- ✓GH/IGF-1 elevation with physiological pulsatile pattern preservation
- ✓Cognitive benefits in mild cognitive impairment (Phase II trial data)
Dosing Protocol
| Typical Dose | 1-2 mg/day |
| Frequency | 1× daily |
| Half-Life | ~26-38 minutes |
| Common Vial Sizes | 2 mg |
Dosing Protocols
FDA-Approved (Lipodystrophy)
Longevity / Body Composition
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 1000–2000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 771 mcg | 1157 mcg | 1543 mcg |
| 140 lb(63 kg) | 900 mcg | 1350 mcg | 1800 mcg |
| 160 lb(73 kg) | 1043 mcg | 1564 mcg | 2086 mcg |
| 180 lb(82 kg) | 1171 mcg | 1757 mcg | 2343 mcg |
| 200 lb(91 kg) | 1300 mcg | 1950 mcg | 2600 mcg |
| 220 lb(100 kg) | 1429 mcg | 2143 mcg | 2857 mcg |
| 250 lb(113 kg) | 1614 mcg | 2421 mcg | 3229 mcg |
💉 For exact syringe units based on your vial concentration, use the Tesamorelin Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Visceral Fat / Lipodystrophy
HighFDA-approved for HIV lipodystrophy. RCT data shows 15-20% VAT reduction in 26 weeks.
GH Optimization / Body Composition
ModerateOff-label use. Preserves pulsatile GH rhythm vs. exogenous GH. Favorable safety profile.
Cognitive Enhancement
ModerateClinical studies show improved cognitive function in older adults with abdominal obesity.
Reconstitution Example
Safety & Considerations
FDA-approved (Egrifta). Generally well-tolerated. Injection site reactions are common. Monitor IGF-1 levels — discontinue if levels exceed normal range. Contraindicated in active malignancy or hypersensitivity.
Regulatory & Legal Status
FDA-approved as Egrifta® for HIV-associated lipodystrophy
Competitive athletes subject to anti-doping controls should not use Tesamorelin.
Prescription Drug
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
GH/IGF-1 elevation affects glucose metabolism — monitor blood glucose. Contraindicated with active malignancy. Not for use in pregnancy. Simvastatin and other glucocorticoids may reduce efficacy.
Synergies & Common Stacks
Tesamorelin (GHRH analog) + Ipamorelin (GHRP) creates the same synergistic mechanism as Mod GRF + Ipamorelin, with tesamorelin's longer half-life offering slightly more convenience.
Tesamorelin reduces visceral fat via GH stimulation; AOD-9604 directly targets adipose tissue lipolysis. Complementary fat loss mechanisms.
Tesamorelin vs. Sermorelin
| Attribute | Tesamorelin | Sermorelin |
|---|---|---|
| FDA Status | FDA-approved (Egrifta® — HIV lipodystrophy) | Not FDA-approved (was revoked) |
| Half-Life | ~26 minutes | ~11–13 minutes |
| Potency | Stronger — engineered GHRH analog | Moderate — native GHRH fragment |
| Best For | Visceral fat + GH deficiency protocol | Anti-aging GH optimization |
| Cost | Higher (Rx only) | Lower (compounded) |
Verdict: Tesamorelin is the clinically superior GHRH analog with proven visceral fat reduction and FDA medical validation. For users specifically targeting body composition and clinical evidence, tesamorelin is the preferred choice.
Featured In Clinical Protocols
Precision Fat Loss & Metabolic Reset
Evidence-based approaches targeting multiple metabolic pathways—GLP-1, GIP, glucagon, and GH axes—for sustainable body composition change backed by Phase 3 clinical trial data showing 15–24% body weight reductions.
Weight Loss Plateau Breakthrough
Overcome metabolic adaptation and aggressively target visceral fat that refuses to burn through caloric deficits alone.
Dosing Quick Reference
Frequently Asked Questions
What makes tesamorelin different from CJC-1295?▼
How does tesamorelin reduce visceral fat?▼
References
- Falutz J et al. “"Tesamorelin (Egrifta) for HIV-Associated Lipodystrophy".” NEJM (2010). PMID: 20427810
Get Tesamorelin from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review